[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse MLEC

Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type I membrane protein
Domain PF11721 Di-glucose binding within endoplasmic reticulum
Function

Carbohydrate-binding protein with a strong ligand preference for Glc2-N-glycan. May play a role in the early steps of protein N-glycosylation (By similarity).

> Gene Ontology
 
Biological Process GO:0006457 protein folding
Molecular Function GO:0030246 carbohydrate binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-6798695: Neutrophil degranulation
R-HSA-597592: Post-translational protein modification
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MLEC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MLEC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.63 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MLEC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1840.451
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1980.94
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.170.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1970.457
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1240.951
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2870.909
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.060.903
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0820.972
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1920.942
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4920.823
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.790.816
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0920.191
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MLEC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MLEC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MLEC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MLEC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MLEC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MLEC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMLEC
Namemalectin
Aliases KIAA0152
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MLEC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.